SHANGHAI, Oct. 29, 2015 /PRNewswire/ -- Gilead Sciences, Inc., and WuXi PharmaTech (Cayman) Inc. (NYSE: WX), today announced that they have entered into a strategic partnership to conduct analytical and stability studies of small-molecule new chemical entities to support global marketing applications and commercial products.
Under the agreement, WuXi will equip and operate a dedicated, fully cGMP-compliant 12,500-square-foot analytical testing facility in Shanghai. The facility will provide analytical and stability services, including analytical method development, transfer and validation for IND/NDA submissions; commercial API and drug product testing; stability studies of APIs, drug products for registration, and commercial products; and reference standard qualification.
"This strategic partnership further strengthens our close, broad-based collaboration with Gilead over many years," said Ge Li, PhD, Chairman and CEO of WuXi PharmaTech. "WuXi is determined to enable our innovative partners like Gilead through our open-access R&D platform, and we are very honored to help advance some of the most innovative medicines faster to patients."
"The opening of this analytical and stability testing center is an important milestone in the ongoing long-term relationship between Gilead and WuXi," said Bob Miller, Vice President of Quality Assurance - Gilead Sciences.
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.
About WuXi PharmaTech
WuXi PharmaTech is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China and the United States. As a research-driven and customer-focused company, WuXi PharmaTech provides a broad and integrated portfolio of services throughout the drug and medical device R&D process. WuXi is also building a platform to provide clinical diagnostic services directly to physicians and their patients globally. WuXi PharmaTech's services are designed to assist its global partners in shortening the cycle and lowering the cost of drug and medical device R&D. WuXi PharmaTech's operating subsidiaries are known as WuXi AppTec. For more information, please visit: http://www.wuxiapptec.com.
For more information, please contact:
Amy Flood (Media)
Vice President, Public Affairs, Gilead Sciences
Ronald Aldridge (Investors)
(617) 374-8800 x109
Aaron Shi (Media)
Director, Corporate Communications, WuXi PharmaTech
SOURCE WuXi PharmaTech (Cayman) Inc.